The cumulative proportion of patients who had ever gained 15 letters or more from baseline by month 12 was 50 % ( sham ) , 68 % ( ranibizumab 0.3 mg ) , and 71 % ( ranibizumab 0.5 mg ) in BRAVO and 42 % , 61 % , and 66 % , respectively , in CRUISE .